Clinical Trial Update: Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide [Phase 2]

View source ↗

Summary

Phase 2 hospital-based trial evaluating inhaled nitric oxide for severe cardiopulmonary disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Transplant
• Lung Disease
• Lung Transplant
• Pulmonary Hypertension
• Sickle Cell Disease

Drugs mentioned

• INOmax (nitric oxide)

Snippet

Sponsor: Mallinckrodt | Conditions: Pulmonary Hypertension, Lung Disease | Phase 2 | Status: TERMINATED